NDAINTRAVENOUSSOLUTION
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
FLYRCADO (flurpiridaz f-18) by Bayer is positron emitting activity [moa]. First approved in 2024.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLYRCADO (flurpiridaz F-18) is a positron-emitting radioactive diagnostic agent administered intravenously as a solution for cardiac PET imaging. It works by emitting positrons that enable visualization of myocardial perfusion and viability in patients with suspected or known coronary artery disease. This first-in-class agent represents a significant advancement in non-invasive cardiac diagnostics.
Growth15.8 years to LOE
Recent approval in growth phase signals expansion of cardiac imaging portfolio and ramp-up of commercial infrastructure, particularly in nuclear medicine and cardiology channels.
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on FLYRCADO at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.